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Abstract
The glucagon receptor (GCGR) is a member of the class B G protein–coupled receptor family. Activation of GCGR by
glucagon leads to increased glucose production by the liver. Thus, glucagon is a key component of glucose homeostasis by
counteracting the effect of insulin. In this report, we found that in addition to activation of the classic cAMP/protein kinase A
(PKA) pathway, activation of GCGR also induced b-catenin stabilization and activated b-catenin–mediated transcription.
Activation of b-catenin signaling was PKA-dependent, consistent with previous reports on the parathyroid hormone
receptor type 1 (PTH1R) and glucagon-like peptide 1 (GLP-1R) receptors. Since low-density-lipoprotein receptor–related
protein 5 (Lrp5) is an essential co-receptor required for Wnt protein mediated b-catenin signaling, we examined the role of
Lrp5 in glucagon-induced b-catenin signaling. Cotransfection with Lrp5 enhanced the glucagon-induced b-catenin
stabilization and TCF promoter–mediated transcription. Inhibiting Lrp5/6 function using Dickkopf-1(DKK1) or by expression
of the Lrp5 extracellular domain blocked glucagon-induced b-catenin signaling. Furthermore, we showed that Lrp5
physically interacted with GCGR by immunoprecipitation and bioluminescence resonance energy transfer assays. Together,
these results reveal an unexpected crosstalk between glucagon and b-catenin signaling, and may help to explain the
metabolic phenotypes of Lrp5/6 mutations.
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Introduction
G protein–coupled receptors (GPCRs) with seven-transmem-
brane domains form a large family that respond to extracellular
signals by activating heterotrimeric G proteins. The glucagon
receptor (GCGR) is a class B GPCR. Its ligand, glucagon, is a 29-
amino acid peptide secreted by the islet A cells of the endocrine
pancreas. The binding of glucagon to its receptor activates the
cAMP/protein kinase A (PKA), protein kinase C (PKC), and
mitogen-activated protein kinases (MAPK) pathways [1,2]. The
major action of glucagon is to increase glucose production from
the liver by stimulating glycogenolysis and gluconeogenesis.
Together with insulin, glucagon is an important regulator of
glucose homeostasis.
Frizzled (Fz) receptors, which are known as atypical GPCRs, are
receptors for the Wnt family of secreted glycoproteins [3]. The
binding of Wnt ligands to Fz receptors activates either canonical or
noncanonical Wnt pathways depending on the cellular context [4];
these are distinct from classical GPCR signaling pathways. The
Wnt/b-catenin pathway is initiated by Wnt protein binding
simultaneously to a Fz receptor and its co-receptor low-density-
lipoprotein receptor–related protein 5/6 (Lrp5/6), causing dis-
ruption of the destruction complex which normally targets b-
catenin for ubiquitin-dependent proteasomal degradation. This
ultimately results in accumulation of b-catenin in the cytosol,
which can then translocate into the nucleus to activate Wnt target
gene expression with TCF transcription factors [5]. The canonical
Wnt pathway plays an essential role in many stages of
development, in stem cell renewal, and in tissue homeostasis
[3,6,7]. Lrp5 and Lrp6 belong to a subfamily of low-density-
lipoprotein receptor–related proteins that are indispensable
components of the canonical Wnt signaling pathway [5].
A number of classical GPCRs have been shown to cross-talk or
activate the b-catenin pathway in a Wnt-independent manner by
various mechanisms. The stimulation of a-adrenergic receptors on
cardiomyocytes (acting through the heterotrimeric G alpha
subunit, Gq), or prostaglandin E2 receptors on colon cancer cells
(acting through the G alpha subunit, Gs) results in the stabilization
of b-catenin and the activation of b-catenin signaling [8,9].
Activation of parathyroid hormone receptor type 1 (PTH1R)
increases b-catenin levels and b-catenin-mediated transcription
through cAMP/PKA-dependent inactivation of glycogen synthase
kinase 3b (GSK-3b) in UMR106 [10] and Saos-2 mouse
osteoblastic cells [11], and through both PKA and PKC
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glucagon-like peptide 1 receptor (GLP-1R) by glucagon-like
peptide-1 (GLP-1) and exendin-4 (Exd4) peptides induces b-
catenin signaling through the activation of cAMP/PKA and AKT
pathways [13].
It was reported that binding of parathyroid hormone (PTH) to
its receptor PTH1R induces activation of the b-catenin pathway
through Lrp6 [14], yet another report suggested that PTH
activates b-catenin signaling in a LRP5/6- and Wnt-independent
manner [15]. So, whether b-catenin signaling activated through
PTH1R requires Lrp6 remains a topic of debate. Mutations in
Lrp5/6 are associated with bone disorders, abnormal ocular
vascularization, early onset cardiovascular disease and metabolic
syndrome [5,16,17]. These phenotypes may not all be attributable
to altered responses to Wnt proteins. For instance, in eye
vascularization, Lrp5 functions in a Norrin-mediated b-catenin
signaling pathway [18]. Moreover, it was recently discovered that
Lrp6 is not only a coreceptor for the Wnt/b-catein signaling
pathway, it is also required for cAMP production for Gas-coupled
GPCRs including PTH1R and GCGR [19]. Because PTH1R,
GLP-1R, and GCGR are well-known targets involved in
regulating bone development and glucose metabolism and the
genetic link between Lrp5/6 mutations and bone and metabolic
disorders, we hypothesize that Lrp5/6 plays a role in mediating
the b-catenin pathway induced by activation of these receptors.
Consistent with previous studies on PTH1R [10,14] and GLP-1R
[13], in this study we found that activation of GCGR by glucagon
also induced the b-catenin signaling pathway. Importantly, we
found that Lrp5/6 is required for glucagon-induced b-catenin
signaling. These results may help to explain the pleiotropic
phenotypes of Lrp5 and 6 mutations and have important
implications in understanding the role of Lrp5/6 in metabolic
syndrome.
Results
Glucagon agonist induced the cAMP/PKA pathway in
GCGR-expressing cells
As a classical GPCR, activation of the glucagon receptor causes
an increase of intracellular cAMP level, which in turn activates the
PKA signaling pathway to activate cAMP-response element
(CRE)-mediated gene expression. Using the CRE-Luc reporter
construct, we found that HEK293 without GCGR transfection did
not respond to GCG1-29 stimulation (Fig. 1B). After transfecting
with GCGR, HEK293 cells became responsive to GCG1-29 (a
GCGR agonist), but not to GCG9-29 (an antagonist) (Fig. 1B). As
a control, forskolin, a direct PKA activator, activated CRE
luciferase activity independent of GCGR expression. Using
western blot, we confirmed that HEK293 cells have no detectable
expression of GCGR until after transfection with a GCGR
expression plasmid (Fig. 1A). These experiments suggest that
HEK293 cells can be used to model GCGR signaling after ectopic
expression of the receptor. We also asked if we could detect CRE
luciferase activity in cells with endogenous GCGR expression.
Primary liver hepatocytes are known to have endogenous GCGR
expression [20]. We found that the GCG1-29 could directly
activate CRE luciferase activity in primary liver cells without the
need to transfect with a GCGR plasmid (Fig. 1C).
Glucagon agonist induced b-catenin signaling in GCGR-
expressing cells
To check whether glucagon can activate the b-catenin signaling
pathway, we first used HEK293 cells transfected with the GCGR
receptor. Treatment with the agonist GCG1-29 increased b-
catenin protein levels relative to a control, non-treated sample
(NT) or that treated with the antagonist GCG9-29 (Fig. 2A). As a
positive control, treatment with lithium chloride (LiCl) also caused
an increase in b-catenin levels, an indication of activation of the
Wnt/b-catenin signaling pathway. To confirm this result, we also
examined cells with endogenous GCGR expression, including the
hepatocarcinoma cell line Hep3B and primary liver cells.
Treatment of Hep3B cells with GCG1-29 caused a rapid increase
of b-catenin protein levels within 15 minutes (Fig. 2B). Treatment
of primary hepatocytes also caused an increase in b-catenin
protein (Fig. 2C). These experiments demonstrate that activation
of the GCGR receptor in cell lines and primary cells leads to b-
catenin stabilization.
Activation of the b-catenin pathway leads to stabilization of b-
catenin in the cytosol, which can translocate into the nucleus and
associate with TCF transcription factors to activate TCF
promoter–mediated gene expression. Because we observed the
stabilization of b-catenin protein upon activation of GCGR
receptor, we next examined whether activation of GCGR
stimulated TCF promoter–mediated luciferase activity, an indica-
tor for an active b-catenin signaling pathway. 293STF cells
(HEK293 cells stably transfected with TCF-Luc reporter DNA)
[18] were transfected with the GCGR receptor and then treated
with GCG1-29 or GCG9-29 peptides. We observed a small but
statistically significant increase in TCF-mediated luciferase activity
upon treatment with GCG1-29, but not with GCG9-29 (Fig. 3A).
Treatment with LiCl also caused an increase in TCF luciferase
activity (Fig. 3A). Similarly, we observed a dose-dependent
increase in TCF luciferase activity in primary hepatocytes treated
with GCG1-29, but not with GCG9-29 or PTH1-34 peptides
(Fig. 3B). These experiments demonstrate that activation of the
GCGR receptor increases TCF promoter activity. Together with
the western results (Fig. 2), they demonstrated that activation of
GCGR receptor leads to active b-catenin signaling.
Coexpression of Lrp5 potentiated glucagon and GLP-1-
induced b-catenin signaling
We observed an increase in b-catenin protein level and TCF-
mediated luciferase activity upon activation of GCGR. Because
Lrp5/6 is an essential coreceptor for Wnt/b-catenin signaling, we
asked whether cotransfection with Lrp5/6 will potentiate gluca-
gon-induced b-catenin signaling. HEK293 cells transfected with
GCGR had a modest increase in b-catenin protein level upon
GCG1-29 treatment, whereas cotransfection with GCGR and
Lrp5 caused a larger increase (Fig. 4A). Next, we examined the
effect of coexpression of GCGR and Lrp5 on glucagon-induced
TCF luciferase activity. As expected, we observed a larger increase
(2 to 3-fold vs 1.5-fold) in glucagon-induced TCF luciferase activity
in HEK293 cells cotransfected with GCGR and Lrp5, relative to
cells transfected with GCGR alone (Fig. 4B & 3A). As a control,
transfection with high dose of Lrp5 alone also caused a small
increase in TCF luciferase activity, which was not responsive to
GCG1-29 treatment (Fig. 4B). Similar results were obtained when
HEK293 cells were cotransfected with GCGR and Lrp6 plasmids
(data not shown). Considering the report that GLP-1 also induced
b-catenin signaling in GLP1R expressing cells [13], we examined
the role of Lrp5 in GLP-1-induced b-catenin signaling. We found
that cotransfection of HEK293 cells with GLP-1R and Lrp5
increased GLP1 agonist induced TCF luciferase activity to a
similar level as observed for cotransfection of HEK293 cells with
GCGR and Lrp5 (Fig. 4C). This is consistent with the hypothesis
that there is a common mechanism for activation of the b-catenin
signaling pathway through both GCGR and GLP1R receptors.
Glucagon Induced b-Catenin Signaling Pathway
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33676Figure 1. Glucagon agonist activates the CRE-Luc activity in GCGR-expressing cells. A). Protein expression for GCGR in HEK293 cells and
primary hepatocytes (isolated from BL/6 mice). HEK293 cells cultured in 6-well plate were transfected with 2000 ng of pcDNA3.1 (empty vector),
GCGR or HA tagged GCGR for 24 h and cells were lysed for western blot analysis as described. B). HEK293 cells cultured in 24-well plate were
transfected with pcDNA3.1 and CRE-Luc (50 ng each) or CRE-Luc and GCGR plasmids (50 ng each) along with 5 ng TKRlu (an internal control) on day
1; cells were treated with or without the glucagon agonist GCG1-29 (50 nM), the antagonist GCG9-29 (50 nM) or forskolin (FSK, 10 mM) on day 2, and
were harvested for luciferase activity measurements after about 17 h on day 3. Triplicate samples were used for each treatment. In all experiments,
the CRE promoter–driven firefly luciferase activity was normalized to Renilla luciferase activity driven by the thymidine kinase promoter (for
transfection control). Luc activity for non-treated group was set to 1 and Luc activities for treated groups were adjusted accordingly. *p,0.005
compared with the non-treated group. C). Primary hepatocytes cultured in 12-well plates were transfected with CRE-Luc (400 ng) and TKRlu (10 ng)
plasmids on day 1, then treated with or without 50 nM GCG1-29 on day 2 and harvested on day 3 for luciferase activity measurement. Duplicate
samples were used for each treatment. *p,0.001 compared with the non-treated group.
doi:10.1371/journal.pone.0033676.g001
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dependent
To understand the mechanism of glucagon-induced b-catenin
signaling, we first asked whether glucagon-induced cAMP/PKA
activity is required for activating the b-catenin pathway. HEK293
cells were transfected with GCGR and treated with GCG1-29 and
H89, a PKA inhibitor. Inhibition of PKA activity completely
blocked the activation of the b-catenin pathway induced by
GCG1-29 (Fig. 5A). In another experiment, HEK293 cells were
cotransfected with GCGR and Lrp5 and then treated with GCG1-
29 in the presence or absence of H89 inhibitor. Treatment with
H89 also completely abolished glucagon-induced b-catenin
transcription activity (Fig. 5B). In these two experiments, we
demonstrated that the glucagon-induced b-catenin signaling
required PKA activity, consistent with previous reports on GLP-
1R [13] or PTH1R [10,11].
Inhibition of Lrp5/6 blocked glucagon-induced TCF
reporter activity
We next asked whether inhibition of Lrp5/6 would reduce
glucagon-induced b-catenin signaling, and we used two approach-
es. First, we used a dominant negative inhibitor of Lrp5/6, the
Lrp5 extracellular domain (ECD) [21,22]. Lrp5ECD inhibited
glucagon-induced TCF luciferase activity when HEK293 cells
were transfected with GCGR alone or GCGR+Lrp5 (Fig. 6A). In
the other approach, we used Dickkopf-1 (DKK1), a known
inhibitor of Lrp5/6, to block Lrp5/6 activity. In this experiment,
DKK1 completely blocked glucagon-induced TCF luciferase
activity when HEK293 cells were transfected with either GCGR
alone or GCGR+Lrp5 (Fig. 6B). These two experiments
demonstrated that inhibiting Lrp5/6 activity blocked the gluca-
gon-induced b-catenin signaling, suggesting that Lrp5/6 is
required for glucagon-induced b-catenin dependent transcription.
Lrp5 physically interacts with GCGR
Because cotransfection with GCGR and Lrp5 increases
glucagon-induced b-catenin stabilization and TCF luciferase
activity, we examined whether GCGR and Lrp5 physically
interact with each other by immunoprecipitation. HEK293 cells
Figure 2. Glucagon agonist induces b-catenin stabilization in
GCGR-expressing cells. A). Lanes 1–3, HEK293 cells cultured in 6-well
plate were transfected with 2000 ng GCGR for 24 h and then either left
non-treated(NT) or treated with 50 nM of glucagon agonist (GCG1-29)
or antagonist (GCG9-29) for 1 h. Lanes 4–5, HEK293 cells cultured in 6-
well plate were transfected with 2000 ng pcDNA3.1 empty vector for
24 h and then treated without or with 20 mM LiCl for 1 h. The cells
were harvested and lysed, and equal amounts of protein for each
sample were used for western blot analysis. The blot was first probed
with anti-b-catenin antibody, then stripped and reprobed for anti-b-
actin antibody as a loading control. B). Hep3B hepatocarcinoma cells
were serum starved for 4 h and then treated with 50 nM GCG1-29 for
the indicated time in serum-free medium. The cells were harvested and
lysed. Cell lysates were used for western blot analysis. C). Mouse
primary hepatocytes were treated without or with 50 nM GCG1-29 for
1 h and cells were harvested and lysed for western blot analysis.
doi:10.1371/journal.pone.0033676.g002
Figure 3. Glucagon agonist activates the b-catenin signaling in
GCGR-expressing cells. A). 293STF cells cultured in 24-well plate
were transfected with 100 ng GCGR and 10 ng TKRlu plasmids on day 1
and then treated with the indicated amounts of GCG1-29, GCG9-29, or
LiCl, a positive control on day 2. Cells were harvested on day 3 for
luciferase activity measurements. Triplicate samples were used for each
group. *p,0.005 compared with the non-treated (NT) group. B).
Primary liver cells cultured in 12-well plates were transfected with
400 ng TCF-Luc and 10 ng TKRlu plasmids on day 1 and then treated
with the indicated amounts of GCG1-29, GCG9-29, or PTH1-34 on day 2.
Cells were harvested for luciferase activity measurement on day 3.
Duplicate samples were used for each treatment.
#p,0.02, *p,0.005
compared with the non-treated group.
doi:10.1371/journal.pone.0033676.g003
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Using western blots, we found that both proteins were well
expressed (Fig. 7A). If we immunoprecipitated a cell lysate using
anti-HA antibody to pull down HA-tagged GCGR, Lrp5 was co-
immunoprecipitated (Fig. 7B). Consistent with this, using v5
antibody to pull down v5-tagged Lrp5, we also pulled down
GCGR protein. We also saw a diffused band above the band with
expected molecular weight for GCGR in the immunoprecipitated
samples (Fig. S5), which may be a nonspecific band picked up by
the HA antibody. We found that the association of GCGR and
Lrp5 was independent of GCG1-29 treatment. As controls,
immunoprecipitation with normal mouse IgG did not pull down
either protein; further, anti-HA antibody did not pull down v5-
tagged Lrp5 and anti-v5 antibody did not pull down HA-tagged
GCGR. Similarly, GCGR was co-immunoprecipitated with Lrp6
in a glucagon-independent manner (Fig. S1). To further confirm
the immunoprecipitation results, we used bioluminescence reso-
nance energy transfer (BRET) assay to examine GCGR and Lrp5
interaction by tagging GCGR with YFP and Lrp5 with Rlu,
respectively. In the static BRET assay, we found that GCGR
interacts with Lrp5 with a BRET ratio of 0.28, which is
significantly above the background of 0.12 (Fig. 7C). As a negative
control, Lrp5 did not interact with the non-structurally-related
CCK1 receptor. Also coexpression of untagged GCGR or Lrp5
competitively inhibited the BRET signal between Rlu-tagged Lrp5
and YFP-tagged GCGR (Fig. 7C). The positive BRET signal was
further confirmed by saturation BRET studies that showed an
increase in BRET signal reaching a plateau, which is indicative of
the existence of an oligomeric complex containing GCGR and
Lrp5 (Fig. 7D). As a negative control, a linear curve was observed
for the CCK1R and Lrp5 BRET signal. Lastly, we checked the
effects of occupation of the GCGR with its natural agonist ligand,
glucagon, on the interaction between GCGR and Lrp5 (Fig. 7E).
We did not find any significant difference in the intensity of the
BRET signal with glucagon concentrations up to 1 mM, which is
well above the saturated concentrations required to elicit full
response. In summary, the immunoprecipitation data and BRET
assay data supports the interpretation that GCGR interacts with
Lrp5 in a ligand-independent manner and ligand treatment did
not significantly change their interaction.
Discussion
In this report, we found that activation of the glucagon receptor
not only led to activation of the classic cAMP/PKA pathway
(Fig. 1), but also activated b-catenin signaling (Fig. 2 and 3). This
activity was specific for glucagon agonists as glucagon antagonists
or other peptides did not elicit the same response (Fig. 2 and 3).
Activation of the b-catenin pathway by glucagon was very rapid
(within 30 min, Fig. 2B), suggesting it is likely to be a direct effect.
This is consistent with other reports which demonstrate that
activation of several GPCRs, including PTH1R [10,11,12] and
GLP-1R [13], leads to up-regulation of the b-catenin pathway
[8,9,23].
PTH1R, GLP-1R and GCGR all belong to class B GPCR
family, which have the closest phylogenetic relationship to Frizzled
receptors [24]. Similar to the Frizzled receptors, these GPCRs, as
reported previously and here, may partner with Lrp5/6 to mediate
b-catenin activation. Lrp6 was reported to play a direct role in
mediating stabilization of b-catenin after exposure of cells to PTH
[14]. We found that Lrp5/6 also has an important role in
glucagon-induced b-catenin signaling. First, cotransfection of
GCGR and Lrp5/6 increased glucagon-induced b-catenin
stabilization (Fig. 4A) and b-catenin-mediated transcriptional
activity (Fig. 4B). Second, inhibiting Lrp5/6 function by a
dominant negative construct (Lrp5ECD) or a functional inhibitor
(DKK1) blocked glucagon-mediated b-catenin signaling (Fig. 6).
One study showed that PTH1R activated b-catenin signaling is
Figure 4. Lrp5 coexpression enhances glucagon and GLP1-
induced b-catenin signaling. A). HEK293 cells cultured in 12-well
plate were transfected with a combination of indicated plasmids (GCGR
1000 ng, Lrp5 500 ng) for 24 h and then treated with or without 50 nM
GCG1-29 for 1 h. The cells were harvested and lysed, and samples were
used for western blot analysis. The blot was first probed with anti-b-
catenin antibody and then stripped and reprobed for anti-b-actin
antibody as a loading control. B). 293STF cells cultured in 24-well plate
were transfected with 100 ng of empty vector (pcDNA3.1) or GCGR
plasmid along with the indicated amount of Lrp5 and 5 ng TKRlu
plasmids on day 1, and then treated with or without 50 nM GCG1-29 on
day 2. Cells were harvested for luciferase activity measurement on day
3. Triplicate samples were used for each treatment. *p,0.005 compared
with non-treated group. 4C). 293STF cells cultured in 24-well plate were
transfected with 100 ng GLP1R, 100 ng Lrp5 and 5 ng TKRlu plasmids
on day 1 and then treated with the GLP1 agonist GLP1(7–36) (50 nM) or
the antagonist Exendin(9–39) (50 nM) on day 2. Cells were harvested on
day 3 to measure luciferase activity. Duplicate samples were used for
each treatment. *p,0.05 compared with the non-treated (NT) group.
doi:10.1371/journal.pone.0033676.g004
Glucagon Induced b-Catenin Signaling Pathway
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lower expression levels of Lrp5/6 in Chinese Hamster Ovary
(CHO) cells and could reflect cell-type specific differences. An
involvement of Lrp6 for PTH [14] and of Lrp5/6 for glucagon
mediated b-catenin signaling may indicate that there is a common
mechanism of signaling for some class B GPCRs including
PTH1R, GLP-1R, and GCGR. Indeed, cotransfection of Lrp5
can also enhance GLP-1 peptide–mediated cross-talk to b-catenin
signaling (Fig. 4C).
Using immunoprecipitation, we found that Lrp5/6 physically
interacted with GCGR (Fig. 7A–B, S1). Using BRET assay, we
further confirmed that ectopic expressed GCGR and Lrp5 do
interact specifically on the cell surface (Fig. 7 C–E). We found that
this interaction is ligand-independent in both experiments, which
is somewhat different from previous report which showed that
PTH1R interacts with Lrp5 in a ligand-independent manner, but
with Lrp6 in a ligand-dependent manner [14]. This difference
may be due to different receptors, cellular contexts or experimen-
tal conditions. Considering that PTH1R and GCGR are different
receptors that can interact with Lrp5/6, one model is that these
interactions may occur via a common adaptor protein to which
GCGR, PTH1R, and Lrp5/6 all can bind, e.g. a G-protein
complex.
Our data suggested that association of GCGR and Lrp5 alone is
not sufficient for activation of the downstream b-catenin pathway.
In addition, ligand binding is required, presumably through
inducing conformational changes of GCGR and phosphorylation
of Lrp5/6 to activate the downstream b-catenin pathway.
However, pre-association of GCGR with Lrp5/6 on the cell
surface can greatly facilitate the signaling communications
Figure 5. Glucagon-induced b-catenin signaling is dependent on PKA activity. A). 293STF cells cultured in 24-well plate were transfected
with 100 ng GCGR and 5 ng TKRlu plasmids on day 1 and then treated with GCG1-29 (50 nM), GCG9-29 (50 nM), or GCG1-29 (50 nM) and PKA
inhibitor H89 (10 mM) on day 2. Cells were harvested on day 3 to measure the TCF-mediated luciferase activity. Triplicate samples were used for each
treatment. *p,0.005 compared with the non-treated group.
#p,0.005 compared with GCG1-29-treated group. B). 293STF cells cultured in 24-well
plate were transfected with 100 ng GCGR, 100 ng Lrp5 and 5 ng TKRlu plasmids on day 1 and then treated with GCG1-29, H89, or both on day 2. Cells
were harvested on day 3 to measure the TCF-mediated luciferase activity. Duplicate samples were used for each treatment. *p,0.02 compared with
the non-treated (NT) group.
#p,0.005 compared with GCG1-29-treated group.
doi:10.1371/journal.pone.0033676.g005
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binding can directly cross-talk to Lrp5/6 to transmit downstream
b-catenin signaling whereas phosphorylation and activation of
Lrp5/6 on the other hand can communicate back to GCGR to
boost GCGR mediated cAMP/PKA pathway. This mutual
communication is supported by our cell-based reporter data
showing that cotransfection of Lrp5 not only enhanced glucagon
induced b-catenin signaling (Fig. 4) but also enhanced glucagon
induced cAMP/PKA signaling (Fig. S2). It is also consistent with
recent studies with PTH1R showing that Lrp6 is not only required
for PTH mediated b-catenin signaling pathway [14], but also
promotes cAMP/PKA signaling [19]. We found that glucagon-
induced b-catenin signaling was dependent on PKA activity
(Fig. 5), which is consistent with other reports for class B GPCRs
such as PTH1R [10,11,12,14] and GLP-1R [13] and suggests that
the b-catenin pathway and cAMP/PKA pathway are intercon-
nected. This is different from Wnt protein–induced b-catenin
pathway, which does not require PKA activity [14]. Interestingly,
treatment of GCGR and Lrp5 expressing cells with glucagon and
Wnt3a conditioned media had a synergistic effect on the b-catenin
signaling pathway, suggesting that the cAMP/PKA pathway and
the b-catenin pathway reinforce each other (Fig. S4).
Glucagon-induced b-catenin signaling is relatively weaker than
Wnt protein-induced b-catenin signaling. The relative weak signal
was not due to lack of interaction between GCGR and Lrp5/6,
but may be intrinsic to GCGR itself. In Frizzled receptors, two
residues in the intracellular loops 1 and 3 (Arg263 and Leu443 in
human Fz5) and a motif in the C-terminal tail (KTXXXW) play
an important role in Dishevelled protein recruitment and Wnt/b-
catenin signaling [25,26]. Sequence analysis indicated that GCGR
lacks these key residues of Frizzled receptors in its intracellular
loops (Fig. S3). The C-terminal motif is not completely conserved
in GCGR (RRXXXW in GCGR, Fig. S3). Note that for PTH1R,
this motif is better conserved (KSXXXW), which may allow better
binding to Dishevelled and more robust b-catenin signaling for
PTH1R.
What is the physiological consequence of cross-talk to b-catenin
signaling from GCGR? Wnt/b-catenin signaling helps to promote
stem cell renewal and in many cases favors proliferation over
differentiation. Several lines of evidence suggest that Wnt/b-
catenin signaling may help pancreatic cells survive and proliferate.
First, Wnt/b-catenin signaling is involved in the genesis of
pancreatic islets and the proliferation of pancreatic beta cells
[27]. Second, polymorphisms in the TCF7L2 gene, one of the
LEF/TCF family members that bind and mediate b-catenin
activity in the nucleus, are highly associated with the risk of type 2
diabetes [28]. Thus activation of the b-catenin signaling pathway
by GLP1 peptide may contribute to regulation of pancreatic islet
cell proliferation [13]. Given the similarity between GLP1R and
GCGR, we speculate that glucagon-mediated activation of b-
catenin signaling may play a similar role in regulating liver cell
proliferation and regeneration. During development, Wnt/b-
catenin signaling often occurs in a temporal and restricted
manner, and overactivation of this pathway leads to cancer
development. Thus, the relative weak signal may be beneficial to
prevent cancer development, while still allowing for self-renewal of
specific cellular populations.
Overall, our results and others suggested that the function for
Lrp5/6 is broader than being a coreceptor for the canonical Wnt
signaling pathway and it can serve as a key scaffold molecule to
participate in both b-catenin and cAMP/PKA signaling pathways.
By engaging with several different GPCRs, it can regulate a range
of important physiological functions including embryonic devel-
opment, bone formation, and metabolism. Our results may help to
explain the pleiotropic phenotypes of Lrp5 and 6 mutations. To
better understand the physiological role of Lrp5/6 in metabolism,
future studies with Lrp5/6 conditional knockout or mutant mice
are needed.
Materials and Methods
Ethics statement
All animal work has been carried out in accordance with US
National Institutes of Health guidelines. All procedures utilized in
this study were evaluating for animal welfare and ethics
considerations and were approved by the VARI Institutional
Animal Care and Use Committee (VARI-IACUC) prior to
initiation (VAI-IACUC protocol ID #09-10-025).
Figure 6. Blocking Lrp5/6 inhibited glucagon-induced b-
catenin signaling. A). 293STF cells cultured in 24-well plate were
transfected with a combination of GCGR (100 ng), Lrp5 (100 ng),
Lrp5ECD (200 ng) and TKRlu (5 ng) plasmids as indicated on day 1, and
then were treated with or without 50 nM GCG1-29 on day 2. Cells were
harvested on day 3 to measure the TCF-mediated luciferase activity.
Triplicate samples were used for each treatment. *p,0.005 compared
with the non-treated (NT) group.
#p,0.005 compared with the group
without the Lrp5ECD transfection. B). DKK1 protein inhibits glucagon-
induced b-catenin signaling. 293STF cells cultured in 24-well plate were
transfected with pcDNA3.1 and GCGR plasmids (100 ng each) or GCGR
and Lrp5 plasmids (100 ng each) along with 5 ng TKRlu plasmid on day
1, and then were treated with 50 nM GCG1-2962 mg/ml DKK1 on day 2.
Cells were harvested on day 3 to measure the luciferase activity.
Duplicate samples were used for each treatment. *p,0.02 compared
with the GCG1-29-treated group.
doi:10.1371/journal.pone.0033676.g006
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33676Figure 7. Lrp5 physically interacts with GCGR. A). HEK293 cells cultured in 6-well plate were transfected with 2000 ng of a control vector (GFP),
v5-tagged Lrp5, HA-tagged GCGR, or both for 24 h and then were treated with or without 50 nM GCG1-29 for 1 h. Cells were harvested and lysed,
and equal amounts of protein were used for western blot analysis. The blot was first probed with v5 antibody and then stripped and reprobed with
HA antibody. The b-actin blot was used as a loading control. B). HEK293 cells were transfected and treated same as in A. The cells were harvested and
lysed, and equal amounts of lysate were immunoprecipitated with the indicated antibody. For HA antibody, the antibody complex was pulled down
by protein G beads. For v5 antibody, it was a single-step pull-down because the antibody was directly conjugated to the agarose beads. After pull-
down, the beads were washed three times with 16TBST and then incubated in 16SDS sample buffer to release the bound proteins. The lysates were
used for western blot analysis and probed with the indicated antibody. C–E). BRET data for Rlu-tagged Lrp5 and YFP-tagged GCGR expressed on COS-
1 cells. Shown are the static BRET signals (C), saturation BRET analysis (D), and effect of natural agonist ligand binding on the BRET signals (E). Shaded
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LiCl was purchased from Sigma Aldrich. The antibodies used
were mouse anti-b-catenin monoclonal antibody (BD Biosciences),
mouse anti-b-actin antibody (Abcam), mouse anti-v5 antibody and
v5 antibody-conjugated agarose beads (Sigma Aldrich), rabbit
anti-GCGR antibody (H-57) (Santa Cruz), and mouse anti-HA
antibody (Covance). Forskolin and H89 were obtained from
Calbiochem. A Dual Luciferase assay kit was purchased from
Promega. GLP-1 peptides, glucagon peptides, and PTH peptides
were purchased from peptide 2.0. Dickkopf-1 (DKK1) protein was
purchased from R&D systems.
DNA plasmids
The TKRlu plasmid with the Renilla luciferase (Rlu) gene under
the control of the thymidine kinase promoter was used as a
transfection control (Promega). The TCF-Luc plasmid (M50
Super 86 TOPFlash), with the firefly luciferase gene under the
control of the TCF promoter, was obtained from Addgene. Mouse
DKK1, Lrp5, Lrp6, and Wnt5-Fz8 plasmids have been described
before [29,30]. The CRE-Luc plasmid (pGL4.29[luc2p/CRE/
Hygro]), with the firefly luciferase gene under the control of the
CRE promoter, was obtained from Promega. The GCGR plasmid
was obtained from Missouri S&T cDNA Resource Center. For
immunoprecipitation, GCGR DNA was cloned into the
pcDNA3.1 expression vector with three tandem HA tags at the
C-terminus by PCR. The Lrp5 extracellular domain (ECD,
residue 32-1375) was cloned into pcDNA6 vector with an Ig k
leader sequence at the N-terminus to allow its secretion into media
supernatant. For BRET studies, the yellow fluorescent protein
(YFP) gene was cloned into the C-terminus of GCGR to create the
GCGR-YFP fusion construct. The Rlu gene was cloned into the
C-terminus of Lrp5 to create Lrp5-Rlu fusion construct. All
constructs were verified by automated DNA sequencing.
Cell lines, mice, and primary cell preparation
HEK293, COS-1 and Hep3B cells were from ATCC. 293STF
cells (which are HEK293 cells with an integrated ‘‘Super-Top-
Flash’’ TCF-luciferase reporter) have been described [18]. C57Bl/
6J mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). Mice were housed under specific pathogen-free
conditions in micro-isolator cages under an American Association
for Laboratory Animal Accreditation and Certification–approved
protocol. Four- to six-week-old mice were used to isolate the
primary hepatocytes. The procedures for isolating primary
hepatocytes have been described previously [31].
Western blot analysis
HEK293 or other cells were cultured in 6-well plates (Costar,
Cambridge, MA). For experiments requiring transfection, cells
were transfected with the indicated DNA using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s protocol. After
transfection, cells were treated with different reagents for the
indicated time. Cell pellets were lysed in 90 mlo f1 6 cell lysis
buffer (Cell Signaling Technology) on ice for 30 min and western
blots were performed as described earlier [32]. The blots were
developed with Pico Chemiluminescence substrate (Pierce Bio-
technology) and exposed to Kodak X-O mat films, which were
scanned on an HP ScanJet flat-bed scanner (Hewlett Packard).
Alternatively, the blots were exposed by using a Biorad Quantity
One Gel Box (Biorad). For reprobing, membranes were stripped
using a solution containing 62.5 mM Tris-HCl, 2% SDS, and
100 mM b-mercaptoethanol at 62uC for 45 min.
Immunoprecipitation
HEK293 cells in 6-well plate were transfected with HA-tagged
GCGR with or without v5-tagged Lrp5 plasmids on day 1 with
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
protocol. On day 2, cells were treated with or without GCG1-29
for 1 h. Cells were subsequently harvested and lysed in 100 mlo f
16cell lysis buffer (Cell Signaling Technology) on ice for 30 min.
Cell debris was removed by centrifugation. The ExactaCruz
TM E
kit from Santa Cruz was used to immunoprecipitate HA-tagged
GCGR from the cell lysate with 2–5 mg mouse anti-HA antibody
according to the manufacturer’s protocol. For immunoprecipita-
tion with v5 antibody, 50 ml of anti-v5 agarose beads were directly
incubated with the cell lysate for 2 h at 4uC with mixing induced
by rotation of the tube. The beads were spun down and washed
three times with 16 TBST (Tris-buffered saline with 0.05%
Tween 20) buffer. Then 50–60 mlo f2 6reducing electrophoresis
buffer was added to the beads and they were incubated at 37uC for
5 min before loading onto an SDS-gel for western blot analysis.
Luciferase assay
To measure the CRE reporter activity, HEK293 cells were
transfected with CRE-Luc DNA. To measure the TCF reporter
activity, either 293STF cells or HEK293 cells transfected with the
TCF-Luc plasmid were used. HEK293 or 293STF cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) with
5% fetal bovine serum (FBS). Cells were plated on a 24-well plate
for 24 h prior to transfection. Cells were transfected in Opti-MEM
I (Invitrogen) with various plasmids+10 ng of control TKRlu
plasmid (constitutive expression of Renilla luciferase) by use of
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
protocol. Cells were induced with the indicated reagents at 24 h
after transfection. Seventeen hours after induction, cells were
harvested and lysed in the plate with 100 mlo f1 6 passive lysis
buffer (Promega) at room temperature for 15 min, and the firefly
and Renilla luciferase activities were measured on an Envision
luminometer (Perkin-Elmer) with the Dual Luciferase assay kit
(Promega). Firefly luciferase data were normalized to Renilla
luciferase data.
BRET studies
BRET experiments were performed using COS-1 cells as
described previously [33]. Cells were seeded at a density of
0.5610
6 cells/dish in sterile 10-cm tissue culture dishes in DMEM
supplemented with 5% Fetal Clone II (Logan, UT). After 24 h, the
cells were transiently transfected with 3 mg of DNA/dish using the
diethylaminoethyl (DEAE)-dextran method [34]. Cells were used
48–72 h later. Receptor-bearing COS-1 cell suspensions of
approximately 25,000 cells/well were used for bioluminescence
and fluorescence measurements in 96-well Optiplates. BRET
area represents the background signal of 0.12 determined using Rlu-tagged Lrp5 with soluble YFP as noted. Coexpression of untagged GCGR or Lrp5
competitively reduced the BRET signals obtained between Lrp5-Rlu and GCGR-YFP (black bars). Saturation BRET analysis supported the specific
interaction of Lrp5 and GCGR. The non-specific bystander type BRET signal (linear) was observed when the non-structurally-related CCK1 receptors
were co-expressed with Lrp5. Incubation with the natural agonist peptide ligand, glucagon (up to 1 mM), did not significantly change the Lrp5 and
GCGR BRET signal. Data are represented as the means 6 S.E.M. from four to six independent experiments performed in triplicate. Data marked with **
were significantly different from background signals at the level of p,0.01.
doi:10.1371/journal.pone.0033676.g007
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luciferase-specific substrate) (Biotium, Hayward, CA) with the cell
suspension. The luminescence signals were collected immediately
using a 2103 Envision fluorescence plate reader configured with
the ,700 nm dichroic mirror and with dual emission filter sets for
luminescence (460 nm, bandwidth 25 nm) and fluorescence
(535 nm, bandwidth 25 nm). Fluorescence of the YFP was
acquired by exciting the samples at 485 nm and collecting the
emission at 525 nm. The BRET ratios were calculated based on
the ratio of emission from YFP and Rlu, as described previously
[33].
Saturation BRET studies were also performed as described
previously [33]. In brief, COS-1 cells were transfected with a fixed
concentration of Rlu-tagged constructs as donor (1.5 mg DNA/
dish) and with increasing concentrations of YFP-tagged constructs
as acceptors (0.3 mgt o6mg DNA/dish). After 48–72 h, BRET
assays were performed. The BRET signals were plotted as ratios
relative to the ratios of emissions of YFP/Rlu, and the curve fit was
evaluated based on R
2 values using Prism 4.0. (GraphPad, San
Diego, CA).
Supporting Information
Figure S1 Lrp6 physically interacts with GCGR. A).
HEK293 cells were transfected with a control vector (GFP), v5-
tagged Lrp6, HA-tagged GCGR, or both for 24 h and then were
treated with or without 50 nM GCG1-29 for 1 h. Cells were
harvested and lysed and used for western blot analysis. The blot
was probed with v5 antibody and then stripped and reprobed with
HA antibody. The b-actin blot was used as a loading control. B).
HEK293 cells were transfected and treated similarly as in A. The
cells were harvested and lysed, and equal amounts of lysate were
immunoprecipitated with the indicated antibody. For HA
antibody, the antibody complex was pulled down by protein G
beads. For v5 antibody, it was a single-step pull-down because the
antibody was directly conjugated to the agarose beads. After pull-
down, the beads were washed three times with 16TBST and then
incubated in 16SDS sample buffer to release the bound proteins.
The lysates were used for western blot analysis and probed with
the indicated antibody.
(TIF)
Figure S2 Coexpression of Lrp5 enhanced the CRE
Luciferase activity. HEK293 cells were transfected with
GCGR or GCGR+Lrp5 plasmids along with CRE-Luc and
TKRlu (an internal control) on day 1. Cells were left untreated or
treated with 50 nM GCG1-29 on day 2. Cells were harvested on
day 3 to measure the luciferase activity as described.
(TIF)
Figure S3 Sequence alignment of the intracellular loop
1 and 3, C-terminal region of Frizzled receptors and
three class B GPCRs. The IC loops and C-terminal region
were predicted by the HMMTOP server [35] and aligned by
clustalW program [36]. The conserved residues critical for
activation of Wnt/b-catenin signaling are highlighted in yellow
based on previous studies [25]. Single mutations abolish Wnt/b-
catenin signaling activity of human Frizzled 5 (Fz5) are indicated
on the top of the alignment [25]. Residue number corresponds to
human Fz5 sequence.
(TIF)
Figure S4 Effects of glucagon and Wnt3a on the TCF Luc
reporter activity in the 293STF cells expressing GCGR
and Lrp5. 293STF cells were transfected with 100 ng each of
Lrp5 and GCGR plasmids and 10 ng of TKRlu (an internal
control) on day 1. Cells were either left untreated, or treated with
50 nM GCG1-29, 10% Wnt3a Conditioned Media (CM) or
50 nM GCG1-29+10% Wnt3a CM on day 2. Cells were
harvested on day 3 to measure the luciferase activity as described
in the ‘‘materials and methods’’ section. The data label indicated
the fold of induction compared with the non-treated group (NT).
(TIF)
Figure S5 The immunoprecipitation experiment using
HA antibody. HEK293 cells were transfected with 2000 ng of
the indicated DNAs and treated with or without 50 nM GCG1-29
for the indicated time, similarly as in Fig. 7. Cells were harvested
and lysed, and cell lysates with equal amounts of protein were used
for western blot analysis for Lane 1–3. For lane 4–10, the cells
were harvested and lysed, and equal amounts of lysate were
immunoprecipitated with HA antibody. The antibody complex
was pulled down by protein G beads. After pull-down, the beads
were washed three times with 16TBST and then incubated in 16
SDS sample buffer to release the bound proteins. The lysates were
used for western blot analysis.
(TIF)
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